Why Precision BioSciences, Inc.’s (DTIL) Stock Is Down 6.54%
As of Wednesday, September 23, Precision BioSciences, Inc.’s DTIL share price has dipped by 6.54%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Commentary & Analysis
Why Precision BioSciences, Inc.’s (DTIL) Stock Is Up 6.77%
As of Tuesday, September 22, Precision BioSciences, Inc.’s DTIL share price has surged by 6.77%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Precision BioSciences, Inc.’s (DTIL) Stock Is Down 5.36%
As of Friday, August 28, Precision BioSciences, Inc.’s DTIL share price has dipped by 5.36%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Precision BioSciences, Inc.’s (DTIL) Stock Is Up 7.41%
As of Wednesday, August 19, Precision BioSciences, Inc.’s DTIL share price has surged by 7.41%, which has investors questioning if this is right time to sell.Michael Rose
Why Precision BioSciences, Inc.’s (DTIL) Stock Is Up 6.49%
As of Tuesday, August 18, Precision BioSciences, Inc.’s DTIL share price has surged by 6.49%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | DTIL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $172.5 | $240.6 | 26% |
|
| Shares Out (Mil) | 25.9 | 54.0 | 34% |
|
| Institutional Ownership | 91.7% | 93.1% | 60% |
|
| Float (Mil) | 25.5 | 41.4 | 33% |
|
| Beta | 1.24 | 0.95 | 73% |
|
| Avg Daily Volume (000s) | 234 | 604 | 46% |
|
| Price Change (52-week) |
10.2% | 49.2% | 62% |
|
| Growth | DTIL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.1% | 12.5% | 46% |
|
| Net Income (5yr) | 16.0% | (10.1%) | 66% |
|
| EPS (5yr) | 43.7% | 15.8% | 90 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.4% | (15.7%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 2 | |
| Current EPS | ($0.890) | ($3.867) | ($1.860) | |
| Month Ago EPS | ($0.890) | ($3.867) | ($1.860) | |
| # Rev Up | 0 | 2 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.647) | ($2.487) | ($1.893) | |
| Year/Year Chg | (29.5%) | 6.4% | (58.7%) | |
| Financials | DTIL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $45 | $37 | 19% |
|
| Net Income (TTM) (Mil) | ($53) | ($44) | 16% |
|
| EPS (TTM) | ($2.590) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($52) | ($34) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $28 | $2 | 65% |
|
| Long-Term Debt (Q1) (Mil) | $27 | $4 | 34% |
|
| Enterprise Value (Q1) (Mil) | $125 | $175 | 23% |
|
| Valuation | DTIL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.65 | 2.30 | 72% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DTIL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 67.3% | 96% |
|
| Net Margin | (117.0%) | (74.8%) | 7% |
|
| ROA | (44.9%) | (47.6%) | 13% |
|
| ROE | (132.9%) | (54.9%) | 7% |
|
| Liabilities to Assets | 64.0% | 29.3% | 59% |
|
| F-Score | 5 | 3 | 50% |
|
Precision BioSciences, Inc. did not pass any screens on 10/7/2026.
